Averin Capital Acquisition Sponsor LLC bought $2.0M of ACAA
See Remarks at Averin Capital Acquisition Corp.. 200,000 shares at an average of $10.00, traded Feb 20, 2025, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.0M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -, 3m -1.2%, 6m -0.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-023169, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2025 | POpen-market purchase Class A Ordinary Shares | +200,000 | $10.00 | $2.0M | 200,000 | Mar 3, 2026 |
Related signals
Other insiders at Averin Capital Acquisition Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | ACAAbuy Averin Capital Acquisition Corp. | Averin Capital Acquisition Sponsor LLC See Remarks | $2.0M 200,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.